Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
(Z)-endoxifen
ATOSSA THERAPEUTICS, INC.
Breast Neoplasms
1 trial -
-
Talion
Primary or advanced breast cancer LumA or ER+ Lobular subtypes.
1 trial -
-
Ningbo Cancer Hospital
Unresectable intrahepatic cholangiocarcinoma
1 trial -
-
Disc Medicine
Intrahepatic cholangiocarcinoma (iCCA)
1 trial -
-, Pred Forte 10 mg/ml colirio en suspensión
AbbVie Deutschland GmbH & Co. KG
platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.
1 trial -
1-(3-(fluoro-18F)benzyl)guanidine ([18F]mFBG)
Disc Medicine
Pheochromocytoma – endocrine adrenal tumor
1 trial -
1/BOB1
Disc Medicine
B-cell Acute Lymphoblastic Leukemia, Multiple Myeloma, Non-Hodgkin B-cell lymphoma
1 trial -
12.5mg sunitinib with Cisplatin and Gemcitabine
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma
1 trial -
13914704178
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
1479-0012
Boehringer Ingelheim
gastroesophageal junction adenocarcinoma, metastatic gastric adenocarcinoma, metastatic breast cancer, metastatic colorectal cancer, esophageal adenocarcinoma
1 trial -
1537-LYMG
Ningbo Cancer Hospital
Advanced stage Hodgkin Lymphoma
1 trial -
1570-CL-0101
Astellas Pharma GmbH
Advanced Solid Tumors
1 trial -
17000139BLC2001
Janssen-Cilag International N.V.
Non-Muscle-Invasive Urothelial Carcinoma (NMIBC) of the Bladder
1 trial -
17000139BLC2002
Janssen-Cilag International N.V.
Muscle-Invasive Urothelial Carcinoma of the Bladder
1 trial -
177Lu girentuximab
Telix Innovations
Advanced Cancer
1 trial -
177Lu-DOTA-EB-FAPI radionuclide therapy
The First People's Hospital of Lianyungang
Refractory Solid Tumor
1 trial -
177Lu-DOTA-TLX591
Telix Innovations
Prostate Cancer
1 trial -
177Lu-J591
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
177Lu-PSMA I&T_IRSTIRCCS
Istituto Gentili S.r.l.
Oligometastatic prostate carcinoma
1 trial -
177Lu-PSMA-617
United Therapeutics Europe Ltd
Metastatic Hormone Naive Prostate Cancer
1 trial -
1801
ACTUATE THERAPEUTICS, INC.
Refractory Hematologic Malignancies or Solid Tumors
1 trial -
19310
Disc Medicine
Head and neck squamous cell carcinoma (HNSCC)
1 trial -
2-deoxyglucose
United Therapeutics Europe Ltd
Prostate Cancer
1 trial -
20-27 PaTcH
Ningbo Cancer Hospital
Metastatic refractory Pancreatic Cancer
1 trial -
2016/2369
The George Institute
pediatric cancer
1 trial -
2017/2558
The George Institute
Resectable mucosal melanomas
1 trial -
20170512
The First People's Hospital of Lianyungang
Triple-Negative Breast Cancer
1 trial -
20180257
Amgen
Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL,
1 trial -
2020-004696-41
The George Institute
Newly diagnosed, non-metastatic early-stage triple-negative or HER2+ breast cancer
1 trial -
2020-S112
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Uterine Cervical Neoplasm
1 trial -
2020/3093 NIRADO
The George Institute
DNA repair-deficient or platinum-sensitive solid tumors
1 trial -
202000570
Disc Medicine
Metastatic solid tumors, these may include but are not limited to melanoma, non-small-cell lung carcinoma (NSCLC), cervical cancer, microsatellite instable (MSI)-high/deficient mismatch repair (dMMR) cancer, renal cell carcinoma (RCC), CSCC, urothelial cell carcer (UCC), small cell lung cancer (SCLC) and head and neck squamous cell carcinoma (HNSCC).
1 trial -
20200491
Amgen
Relapsed/Refractory Small Cell Lung Cancer
1 trial -
2021-SR-545
The First People's Hospital of Lianyungang
Lymphoma, Large B-Cell, Diffuse
1 trial -
2021/3330 HOLMBRAVE
The George Institute
Non resectable Hepatocellular carcinoma (HCC)
1 trial -
20210023
Amgen
Advanced MTAP-null solid tumors
1 trial -
20220127
Amgen
In Part 1, subjects with advanced MTAP-null solid tumors and, in Part 2, subjects with advanced MTAP-null Non Small-Cell Lung Cancer
1 trial -
2023-1-69-001
Ningbo Cancer Hospital
Hepatocellular carcinoma
1 trial -
2023-SR-002
The First People's Hospital of Lianyungang
NK-T-Cell Lymphoma, Extranodal
1 trial -
2023/3610 NEOSARC
The George Institute
Undifferentiated pleomorphic sarcoma and Dedifferentiated liposarcoma
1 trial -
2023/3668
The George Institute
Patients with HER2-positive (HER2-pos) (cohort 1) or HER2-low defined as a score 1+ on immunohistochemistry [IHC] or as an IHC score 2+ and negative results on in situ hybridization (ISH) (cohort 2) ABC, and any hormone receptor (HR) status, who have progressed on trastuzumab deruxtecan (T-DXd). In addition to previous T-DXd, patients with HER2-pos tumors must have received prior treatment with trastuzumab (+/- pertuzumab) and taxanes and may have received T-DM1. Patients with HER2-low tumors must have received prior treatment with taxanes. Patients with HR-positive (HR+) and HER2-low tumor must have received prior treatment with endocrine therapy and CDK4/6 inhibitors.
1 trial -
2024-HS-022
The First People's Hospital of Lianyungang
Platinum-sensitive Relapsed Ovarian Cancer
1 trial -
2024/3967
The George Institute
Advanced non-small cell lung cancer
1 trial -
20240092
Amgen
Small Cell Lung Cancer (SCLC)
1 trial -
2025-SR-813
The First People's Hospital of Lianyungang
Esophageal Cancer
1 trial -
2026（225）
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cancer of Biliary Duct
1 trial -
20289
Bayer AG
Solid tumors harboring NTRK fusion
1 trial -
20290
Bayer AG
Solid tumors harboring NTRK fusion
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.